IGF2 and breast cancer: Linsitinib is a potent competitive IGF-1R/insulin receptor (IR) inhibitor in the autophosphorylation activities of the IGF ligands (e.g., IGF-I and IGF-II), impeding the activation of downstream cascades favoring BC tumorigenesis (e.g., AKT and ERK signaling) [91].